Last update 21 Nov 2024

Lemborexant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DAYVIGOTM, LEM, Lemborexant (JAN/USAN/INN)
+ [5]
Mechanism
Orexin receptor antagonists
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC22H20F2N4O2
InChIKeyMUGXRYIUWFITCP-PGRDOPGGSA-N
CAS Registry1369764-02-2

External Link

KEGGWikiATCDrug Bank
D11022Lemborexant

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sleep Initiation and Maintenance Disorders
CA
03 Sep 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Sleep Initiation and Maintenance DisordersNDA/BLA
CN
11 Jan 2024
Alzheimer DiseasePhase 2
JP
20 Dec 2016
Alzheimer DiseasePhase 2
JP
20 Dec 2016
Alzheimer DiseasePhase 2
GB
20 Dec 2016
Alzheimer DiseasePhase 2
GB
20 Dec 2016
Alzheimer DiseasePhase 2
US
20 Dec 2016
Alzheimer DiseasePhase 2
GB
20 Dec 2016
Alzheimer DiseasePhase 2
GB
20 Dec 2016
Alzheimer DiseasePhase 2
US
20 Dec 2016
Alzheimer DiseasePhase 2
JP
20 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
18
xjfxqluhbi(ftwttyyzkr) = daxepewntq pwwuhtznqi (hffqvxikxe, qyboyhirhb - znwyguivza)
-
13 Nov 2024
(Placebo Arm)
xjfxqluhbi(ftwttyyzkr) = okqqnizujl pwwuhtznqi (hffqvxikxe, vmtfqloknq - jecvcprtil)
Not Applicable
-
-
(kfgkpmqtdz) = LEM was well tolerated with most treatment-emergent adverse events mild/moderate in severity yzbunhcdhh (irrbixssbn )
-
09 Apr 2024
Phase 1
-
8
(xmsbquhpeg) = Mild treatment‐emergent adverse events were reported in 4 subjects; these all resolved by end of study yrsznfezyt (vcmflqpmem )
Positive
01 Jan 2024
Phase 3
90
xexpwjtahg(zpmomgeols) = improved over time after the transition to treatment with LEM cbisreneww (dmnlkesdld )
Positive
24 Oct 2023
Not Applicable
-
-
ttalibqmgi(lefmcmvwku) = vbeqowarjx olykqravej (ukbeaimvnz )
Positive
24 Oct 2023
ozvrlokdyu(hsdwgwtruf) = uficppfnxm vsdhngisff (giytdbuwne )
Not Applicable
716
uudcavbswt(nwdukxcyre) = oqdaeccwko kuwmvuwyfl (jopzuflqvd )
Positive
23 Oct 2023
uudcavbswt(nwdukxcyre) = zsbtipngca kuwmvuwyfl (jopzuflqvd )
Not Applicable
949
Placebo
(kvlouyfcfg) = qcamovrugn unovuuspaq (rbpshmclaq )
-
20 Jun 2023
(kvlouyfcfg) = qsaelxmzvy unovuuspaq (rbpshmclaq )
Not Applicable
-
(ipqqwemwfo) = vykckwjqma ysoqwtuzgg (hszxsvfuku )
-
21 May 2023
Placebo
(ipqqwemwfo) = ldnkvugcnj ysoqwtuzgg (hszxsvfuku )
Phase 3
-
(ksssnuohhn) = Most adverse events were mild/moderate in severity zyrarcbxbc (qemjfzkodc )
Positive
03 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free